Medicare AdvantageCoverageMedium impact
MA08.059l, Ipilimumab (Yervoy®)
Independence Blue Cross·MA · Oncology, Pharmacy·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
Policy MA08.059l for Ipilimumab (Yervoy®) has been updated effective December 29, 2025, with changes to medical necessity criteria, medical coding requirements, and general guidelines. The billing team must review the full policy text to identify specific coding and coverage changes that may affect claim submission and prior authorization processes for this oncology drug.
Action Required
By December 29, 2025: Billing team must obtain and review the complete policy text at https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=12&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#medicare-advantage-ma08-059l-ipilimumab-yervoy to identify specific HCPCS codes, medical necessity criteria, and any prior authorization requirements. Update billing system rules, encounter templates, and provider documentation requirements accordingly. Communicate changes to oncology providers and infusion centers. Claims submitted without compliance to updated criteria may be denied.